

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A liquid pharmaceutical composition comprising an active substance chosen among cetirizine, levocetirizine and efletirizine, and at least one preservative, wherein the amount of preservative is in the case of parahydroxybenzoate esters more than 0 and less than 1.5 mg/ml of the composition, and in the case of other preservatives is such that it leads to the same preservative effects as a parahydroxybenzoate esters concentration of more than 0 and less than 1.5 mg/ml.
2. (Currently Amended) A liquid pharmaceutical composition according to claim 1, ~~characterized in that~~wherein it is an aqueous composition.
3. (Currently amended) A liquid pharmaceutical composition according to claim 1 ~~or 2~~, ~~characterized in that~~wherein the preservative is selected from the group of methyl parahydroxybenzoate, ethyl parahydroxybenzoate, propyl parahydroxybenzoate, a mixture of methyl parahydroxybenzoate and ethyl parahydroxybenzoate or propyl parahydroxybenzoate, and a mixture of methyl parahydroxybenzoate and propyl parahydroxybenzoate.
4. (Currently amended) A liquid pharmaceutical composition according to claim 3, ~~characterized in that~~wherein the preservatives is a mixture of methyl parahydroxybenzoate and propyl parahydroxybenzoate in a ratio of 9/1 expressed in weight.
5. (Currently amended) A liquid pharmaceutical composition according to claim 1, ~~characterized in that~~wherein the pharmaceutical composition contains an amount of p-hydroxybenzoate esters (methyl p-hydroxybenzoate/propyl p-hydroxybenzoate in a ratio of 9/1 expressed in weight) selected in the range of 0.0001 and 1.4 mg/ml of the composition.
6. (Currently amended) A liquid pharmaceutical composition according to claim 1, ~~characterized in that~~wherein the pharmaceutical composition contains an amount of thimerosal selected in the range of 0.0001 and 0.05 mg/ml of the composition.

7. (Currently amended) A liquid pharmaceutical composition according to claim 1, ~~characterized in that~~wherein the pharmaceutical composition contains an amount of chlorhexidine acetate selected in the range of 0.0001 and 0.05 mg/ml of the composition.
8. (Currently amended) A liquid pharmaceutical composition according to claim 1, ~~characterized in that~~wherein the pharmaceutical composition contains an amount of benzylalcohol selected in the range of 0.0001 and 10 mg/ml of the composition.
9. (Currently amended) A liquid pharmaceutical composition according to claim 1, ~~characterized in that~~wherein the pharmaceutical composition contains an amount of benzalkonium chloride selected in the range of 0.0001 and 0.05 mg/ml of the composition.
10. (Currently amended) A liquid pharmaceutical composition according to ~~any of the preceding claims~~claim 1, ~~characterized in that~~wherein the active substance is cetirizine.
11. (Currently amended) A liquid pharmaceutical composition according to ~~any of the claims 1 to 12~~claim 1, ~~characterized in that~~wherein the active substance is levocetirizine.
12. (Currently amended) A liquid pharmaceutical composition according to ~~any of the preceding claims~~claim 1, ~~characterized in that~~wherein the composition is in the form of oral solutions, nasal drops, eye drops or ear drops.